JELLYFISH
23.2.2021 15:02:15 CET | Business Wire | Press release
Jellyfish , the digital marketing partner to the world's leading brands (i.e., Samsung, Uber, Nestle, Deckers, Spotify, and eBay), announced today the acquisition of 5 companies—each a known leader in the digital space. Jellyfish’s rapid expansion comes against a backdrop of consolidation and challenges in the traditional agency sector as the company’s capabilities lie in helping brands during their digital transformation journey. Jellyfish’s expansion follows previous acquisitions with a significant investment from Fimalac Group in 2019. The company represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Launched in 2005, it has also become one of a select few globally managed Google Marketing Platform Partners, growing at an average of 45% per annum consistently over the last eight years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005716/en/
Current eMarketer forecasts indicate that total media ad spend is expected to hit more than 600 billion in 2021 thus, to remain competitive, and to increase media effectiveness, companies must cut through a saturated digital landscape and provide seamless, relevant communications across all channels and touchpoints. The acceleration of digital transformation in response to the global pandemic has created a greater need for brands to partner with companies that can help them navigate and meet the challenges of driving growth and sustainability.
“Our mission is to ensure that our clients have all the resources needed to fully embrace digital transformation and reach results that transcend every expectation. Coming off a year of unprecedented disruption and transformation in digital marketing, Jellyfish continues to grow worldwide, entering new markets of Australia and Mexico and increasing our presence in France, Brazil, and the US—adding new capability and talent around the globe, with a focus on content creation and localization, e-commerce, creative, and data optimization,” says Rob Pierre CEO of Jellyfish. “These acquisitions are key in driving prominence and growth in the marketplace and we believe nothing is impossible or beyond the reach of our clients,” Pierre adds.
“These acquisitions bring powerful enhancements to our portfolio of services by expanding our depth of expertise, geographical reach, and our offerings across several continents and regions,” says Chris Lee, COO, Jellyfish.
Expanded expertise, technologies:
Seelk
Software and consultancy for Amazon Marketplace
Splash
Creative technology and services with global localization
Quill
Global Performance Content for e-commerce
Webedia Brand Services
Gamification, content, data, technology services and enterprise data strategies
Expanded global footprint:
Data Runs Deep - Australia
Consulting, implementation, and training for data solutions
For additional information on each Jellyfish acquisition company, click here .
Other recent acquisitions that expanded our global footprint:
Reamp - Brazil
Programmatic marketing, marketing automation, and digital campaign performance (acquired in H2 2020)
San Pancho - Mexico & Colombia
Full-funnel digital marketing capabilities and analytics expertise (acquired in H2 2020)
About Jellyfish
Jellyfish, part of the Fimalac Group, is a global partner in digital marketing and transformation to some of the world's leading brands including Samsung, Uber, Nestle, Orange, Spotify & eBay. Jellyfish represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Employing over 2000 people across 40 offices globally, and with further expansion on the horizon, Jellyfish aims to be the first-choice global partner for any brand’s digital requirements. Launched in 2005, Jellyfish has also grown to become one of a select few globally managed Google Marketing Partners. Growing at an average of 45% per annum consistently over the last eight years, Jellyfish is proud to be at the forefront of the global digital economy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom